 Connection
Samer Al Hadidi to Aged
This is a "connection" page, showing publications Samer Al Hadidi has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.193 |
|
|
|
-
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
Score: 0.085
-
Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589.
Score: 0.063
-
Schinke C, Rasche L, Ashby C, van Hemert R, Thanendrarajan S, Al Hadidi S, Zangari M, Bailey C, Alapat DV, Shaughnessy JD, Zhan F, Barlogie B, van Rhee F, Weinhold N. Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging. Blood Adv. 2025 Sep 09; 9(17):4368-4377.
Score: 0.023
-
Sun F, Cheng Y, Ma C, Xu H, Bailey C, Mery D, Ashby TC, Alapat D, Li Y, Young KH, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|